May 25th, 2022 (Earnings Report)Dear Reader,
HealthTechMovers.com just identified several healthtech stocks that are expected to release earnings starting today, May 25th.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
22nd Century
Symbol: XXII
Recent Price: $1.27
Average Analyst Price Target: $6.75 (431.50%)
Last Year's EPS: -$0.06
Consensus EPS Forecast: -$0.06
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: James McIlree, analyst at Dawson James, reiterates coverage on 22nd Century (XXII) in the Healthcare sector with a Buy rating and a price target of $ 8.5 (1 month ago).
Click for complete article >>--------------------------------------------------------------------------
AbCellera Biologics
Symbol: ABCL
Recent Price: $11.91
Average Analyst Price Target: $33.00 (177.08%)
Last Year's EPS: -$0.08
Consensus EPS Forecast: $0.06
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Gaurav Goparaju, analyst at Berenberg Bank, reiterates coverage on AbCellera Biologics (ABCL) in the Healthcare sector with a Buy rating and a price target of $ 43 (2 days ago).
Click for complete article >>--------------------------------------------------------------------------
Achilles Therapeutics
Symbol: ACHL
Recent Price: $1.95
Average Analyst Price Target: $20.00 (925.64%)
Last Year's EPS: -$0.34
Consensus EPS Forecast: -$0.65
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Geulah Livshits, analyst at Chardan Capital, reiterates coverage on Achilles Therapeutics (ACHL) in the Healthcare sector with a Buy rating and a price target of $ 20 (2 months ago).
Click for complete article >>--------------------------------------------------------------------------
Aclaris Therapeutics
Symbol: ACRS
Recent Price: $15.16
Average Analyst Price Target: $41.00 (170.45%)
Last Year's EPS: -$0.35
Consensus EPS Forecast: -$0.39
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Julian Harrison, analyst at BTIG, reiterates coverage on Aclaris Therapeutics (ACRS) in the Healthcare sector with a Buy rating and a price target of $ 32 (4 weeks ago).
Click for complete article >>--------------------------------------------------------------------------
Adaptimmune Therapeutics
Symbol: ADAP
Recent Price: $1.6
Average Analyst Price Target: $5.50 (243.75%)
Last Year's EPS: -$0.05
Consensus EPS Forecast: -$0.28
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Mara Goldstein, analyst at Mizuho Securities, reiterates coverage on Adaptimmune Therapeutics (ADAP) in the Healthcare sector with a Hold rating and a price target of $ 9 (1 week ago).
Click for complete article >>--------------------------------------------------------------------------
ADC Therapeutics
Symbol: ADCT
Recent Price: $4.23
Average Analyst Price Target: $15.50 (266.43%)
Last Year's EPS: -$0.93
Consensus EPS Forecast: -$0.35
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Gregory Renza, analyst at RBC Capital, reiterates coverage on ADC Therapeutics (ADCT) in the Healthcare sector with a Buy rating and a price target of $ 25 (4 weeks ago).
Click for complete article >>--------------------------------------------------------------------------
Agenus
Symbol: AGEN
Recent Price: $2.44
Average Analyst Price Target: $8.00 (227.87%)
Last Year's EPS: $0.72
Consensus EPS Forecast: -$0.19
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Mayank Mamtani, analyst at B.Riley Financial, reiterates coverage on Agenus (AGEN) in the Healthcare sector with a Buy rating and a price target of $ 8 (3 weeks ago).
Click for complete article >>--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
